Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide), the N-ethyl derivative of LSD. An adolescent patient developed moderate to severe symptoms as acute aggression, agitation, unconsciousness, multiple traumatic injuries, metabolic disturbances and persistent psychosis following ETH-LAD ingestion and required intensive medical therapy with unexpected findings. The concentration of the hallucinogenic new psychoactive substance in serum was determined with 38 ng mL[-1]. After 17 days of hospitalization, the patient was transferred to a psychiatric clinic for further treatment. Physicians must be aware that ETH-LAD ingestion may, unlike LSD, lead to severe toxic effects, requiring intensive care.

Psychedelic use has greatly increased within clinical and recreational settings over recent years. While demonstrating a favorable safety profile within certain clinical populations, little empirical research has explored safety of psychedelic use within real-world samples. Using the World Health Organization (WHO) VigiBase, a comprehensive global pharmacovigilance database with voluntary spontaneous reporting of adverse events (AEs) from real-world clinical and recreational populations, we examined reports for classic psychedelics and MDMA. Most reports were made for MDMA (n = 1573) and LSD (n = 394), while psilocybin (n = 56), DMT (n = 18), and mescaline (n = 15) had fewer reports. The most common AEs for all substances were psychiatric in nature, specifically surrounding substance or drug abuse and dependence. Reports of overdose constituted 1.1 to 1.7 % of total AEs. Pregnancy-related and congenital disorders were rare. Compared to the acetaminophen control, LSD and MDMA were associated with significantly greater odds for the reported AEs of alcohol abuse (LSD: ROR=45.7, 95 % CI: 27.2 - 76.9; MDMA: ROR=19.2, 95 % CI: 12.2 - 30.4), substance use disorder (LSD: ROR=71.1, 95 % CI: 36.3 - 139.2; MDMA: ROR=129.9, 95 % CI: 78.4 - 215.5) and substance dependence (LSD: ROR=215.1, 95 % CI: 69.0 - 670.3; MDMA: ROR=76.8, 95 % CI: 25.5 - 231.8). These reports were also greater than those associated with the external positive control, oxycodone. Taken together, this exploratory study provides the first analysis of AEs associated with psychedelics reported to a global pharmacovigilance database and can inform their real-world safety. Findings should be considered in light of limitations surrounding co-use of other substances and potential deterrence towards reporting use of illicit substances.

One of the most difficult challenges for any prescriber is distinguishing between the legitimate prescription of controlled substances and the prescription that may be used for illegitimate purposes. To discern the difference, prescribers need to understand the signs, symptoms, and treatment of acute and chronic pain and the signs and symptoms of patients misusing controlled substances. Pain relief remains one of the most common reasons patients seek medical attention. Although many categories of pain medications are available, opioid analgesics are approved by the Food and Drug Administration (FDA) for moderate-to-severe pain. As such, they are a common choice for patients with acute, cancer-related, neurologic, and end-of-life pain. Prescribing opioid analgesics for chronic pain is controversial and fraught with inconclusive standards. In the 1990s, the chronic failure of health professionals to treat severe pain appropriately led to an expansion in opioid analgesic prescribing. Unfortunately, this resulted in increased overuse, diversion of drugs, opioid use disorder, and overdose. The Catch-22 is that health professionals either undertreat patients, leading to unnecessary suffering, or overtreat them, which can cause adverse effects such as increased risk of opioid analgesic use disorder and potential overdose. Opioid analgesic prescribing reached its highest point in 2011. Since then, both prescribing and overdose have been declining. However, as a society, in both the lay and scientific literature, there are significant concerns that we are still in the middle of an opioid crisis. One of the biggest challenges in caring for patients with pain is their varying tolerance levels, which necessitate different opioid doses to achieve adequate pain relief. Patients may exhibit a wide range of behavioral, cultural, emotional, and psychological responses to pain compared to those with a substance use disorder; often, distinguishing between the two can be challenging. All healthcare professionals engaged in pain control need an understanding of the treatment recommendations and safety concerns in prescribing opioid analgesics. Appropriate opioid prescribing requires a thorough patient assessment, short- and long-term treatment planning, close follow-up, and continued monitoring. All healthcare providers need to be aware of appropriate patient assessment, treatment planning, and the potential for substance use disorder, drug diversion, and hazardous behavioral responses to controlled substances, such as opioid analgesics, which differ from pseudoaddiction and physical dependence. Many clinicians have limited knowledge of opioid use disorder. They often fail to recognize it as a disease and mistakenly believe that opioid dependence is the same as opioid use disorder. A lack of clear understanding can lead to confusion between patients with chronic non-use disorder and those misusing their prescribed opioids. A lack of training and educational deficits often interfere with the appropriate prescription of opioid analgesic agents. To prevent the misuse of controlled substances, healthcare providers who prescribe controlled substances should learn prescribing practices that minimize or prevent adverse consequences. Definitions: Addiction: According to the American Society of Addiction Medicine (ASAM), addiction is a primary, chronic disease of brain reward, motivation, memory, and related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, social, and spiritual manifestations. This dysfunction is reflected in an individual pathologically pursuing reward or relief through substance use and other behaviors. Addiction is now termed substance use disorder and is characterized by an inability to consistently abstain, cravings for the drug, impairment in behavioral control, diminished ability to recognize significant problems with one's behaviors and interpersonal relationships, and a dysfunctional emotional response. Like other chronic diseases, substance use disorder often involves cycles of relapse and remission. Without treatment or engagement in recovery activities, substance use disorder is progressive and can result in disability or premature death. : Appropriate opioid analgesic prescribing: This involves providing pain control while minimizing toxicity, substance use disorder, or the risk of substance use disorder and implementing safeguards to reduce drug diversion. Inappropriate opioid analgesic prescribing: Non-prescribing, inadequate prescribing, excessive prescribing, or continued prescribing despite evidence of the lack of effective opioid analgesic treatment. Controlled substances: These substances are drugs or medications that possess the potential for being misused and are considered to be substances that have a substantially high risk of resulting in substance use disorder. Opioid analgesics: These drugs dull the senses and relieve pain, such as morphine. In addition, these medications may induce sleep. The Drug Enforcement Administration (DEA, USA) uses the term narcotic to refer to drugs that are opioid analgesics. Characteristics of Addiction or Substance Use Disorder: Craving for drugs or rewards. Diminished recognition of significant problems in behavior. Dysfunctional emotional response. Impairment in behavioral control. Inability to consistently abstain . Drug Schedules of Controlled Substances All healthcare providers should be familiar with the guidelines and laws for each schedule, which are based on the purpose of the drug and the risk of substance use disorder. In the United States, controlled substances are subject to strict regulation by both federal and state laws that govern their manufacture and distribution. Controlled substances have a high risk of resulting in addiction and substance use disorder. As the schedules decrease from I to V, the drugs listed within each category have a lower potential to cause a substance use or addiction disorder. Controlled Substances Act In the United States, the Comprehensive Drug Abuse Prevention and Control Act was passed in 1970 and included the Controlled Substances Act. The Controlled Substances Act covers various aspects of drugs as follows: Classification and regulation of drugs, according to their content and purpose. Manufacturing of drugs. Distribution of drugs. Exportation and sale of drugs. The Controlled Substances Act established 5 drug schedules to regulate the manufacture and distribution of controlled substances. As part of the regulation, healthcare providers who prescribe controlled substances and pharmacists who fill these prescriptions must obtain a license from the DEA. These licenses include specific license numbers allowing controlled substance prescriptions to be tracked and linked to a specific healthcare provider or distributor. These schedules categorize substances based on their medical value, risk of addiction, and potential to cause harm. The schedules range from Schedule I, which has the highest potential for addiction and substance use disorder, to Schedule V, which has the lowest potential for addiction and substance use disorder. Schedule I: Schedule I drugs possess the highest potential for substance use disorder and misuse. These drugs have no medical use and are illicit or street drugs. Examples of Schedule I drugs include heroin, lysergic acid diethylamide, mescaline, methylenedioxymethamphetamine, and methaqualone. Marijuana, which is legal in some states, is still classified as a Schedule I drug at the federal level as of this writing. Schedule II: Schedule II drugs have a reduced potential for substance use disorder compared to Schedule I. These drugs are at high risk for both physical and psychological dependence. These drugs have a high capacity for both substance use disorder and misuse. Schedule II drugs are typically prescribed to treat severe pain, anxiety, insomnia, and attention-deficit hyperactivity disorder. Examples of Schedule II substances include fentanyl, hydromorphone, meperidine, methadone, morphine, oxycodone, dextroamphetamine, methylphenidate, methamphetamine, pentobarbital, and secobarbital. These drugs were previously prescribed only through a paper prescription, but they are now permitted to be transmitted electronically through Electronic Prescriptions for Controlled Substances (EPCS). No refills are allowed. . Schedule II drugs have the tightest regulations compared to other prescription drugs. Schedule III: Schedule III drugs have a lower misuse potential compared to Schedule I and II drugs. These drugs may cause physical dependence but more commonly lead to psychological dependence. Medications in this category are often used for pain control, anesthesia, or appetite suppression. Examples of Schedule III substances include benzphetamine, ketamine, phendimetrazine, and anabolic steroids. Opioid analgesics in this schedule include products containing not more than 90 mg of codeine per dosage unit and buprenorphine. Schedule III drugs may be prescribed verbally over the phone, with a paper prescription, or through EPCS. Within a 6-month timeframe, refill requirements are such that the drug can only have 5 refills. . Schedule IV: Schedule IV drugs have a lower potential for misuse compared to Schedule I, II, or III drugs. These drugs have a limited risk of physical or psychological dependence. Examples of Schedule IV substances include alprazolam, carisoprodol, clonazepam, clorazepate, diazepam, lorazepam, midazolam, temazepam, tramadol, and triazolam. Drugs in this class may be used for pain control as long as the healthcare provider deems the drug medically necessary and the patient is likely to benefit. Schedule IV drugs can be prescribed verbally over the phone, with a paper prescription, or through EPCS. Refills are permitted up to 5 times in a 6-month timeframe from the issuance date. Schedule V: Schedule V drugs are the least likely of the controlled substances to be misused. These drugs result in minimal physical or psychological dependence. Examples include cough medicines containing codeine, antidiarrheal medications containing atropine or diphenoxylate, pregabalin, and ezogabine. Despite their low abuse potential, they still need to be managed appropriately and administered with care. When these medicines contain codeine, they must have less than 200 mg of codeine per 100 mL. Partial prescription fills cannot occur more than 6 months after the issue date. When a partial fill occurs, it is treated in the same manner and with the same rules as a refill of the drug. Drug Use Disorder, Abuse, and Misuse Drug use disorder differs from drug abuse and misuse. Drugs taken may be illicit street drugs, stolen drugs, or those obtained through a legal prescription. Misusing a drug typically involves taking the drug in a harmful or detrimental way, resulting in personal, professional, or social problems. A patient abusing an opioid analgesic may no longer be able to interact appropriately with their family or friends and perform their duties at work. Misuse of a controlled substance refers to using a prescribed drug in a way that was not intended, whether intentionally or accidentally. A negative result may or may not occur. Examples of misuse include taking too much of a drug, using an incorrect dose, an incorrect route, or using prescription drugs written for another person. Controlled substances include both prescription drugs and illicit drugs with no recognized medical value. Both categories have the potential to be abused or misused. Although the use of Schedule I drugs is illegal, prescription drugs found in Schedules II through V are also commonly abused and misused, and their misuse is a challenging problem that has increased over the last several years. The Centers for Disease Control and Prevention (CDC) has declared prescription drug abuse a problem of epidemic proportions. The CDC believes that the absence of checks and balances on the prescription and distribution of controlled substances, including those prescribed for medical use, has the potential for abuse, and misuse is likely to continue increasing. Prescriber Shopping A common practice among individuals who intentionally misuse controlled substances is to seek multiple sources for drugs. These individuals visit different healthcare providers, presenting a list of complaints that are often fictitious and vary from one healthcare provider to another. As a result, they may be able to obtain multiple prescriptions, which they then fill at different pharmacies. To combat this practice, known as prescriber shopping, many states have implemented systems that enable healthcare providers to view all the prescriptions written for each patient. The use of these systems is helping to gradually reduce such misuse. Diversion Some prescription drugs can be sold on the street for as much as $50 per tablet. Diversion is when a patient sells their drugs as a method of earning money. Patients may also sell their drugs to buy food, pay expenses, or purchase more potent street drugs. In some worst cases, healthcare providers may divert drugs from patients for their personal use or sell them to others. Some individuals use controlled substances for purposes other than their intended medical use. Rather than pain control, they may be used to stay awake, induce sleep, or get high. Before the popularity of prescription drug diversion, the only method to obtain illicit drugs was to import from other countries or manufacture them in private labs. Today, law enforcement agencies have the tremendous challenge of dealing with prescription drugs sold by diversion and illicit drugs imported or manufactured. In both instances, these drug sales and usage result in increased criminal activity, dangerous overdoses, and death.  Methods of Obtaining Prescription Drugs A review of multiple studies highlights a variety of ways individuals obtain prescription drugs. The findings are summarized below: 55% free from a friend or relative. 20% from a prescriber. 10% purchased from a friend or relative. 5% stolen from a friend or relative. 5% purchased from a drug dealer. 2% from multiple doctors. 1% through theft from a medical practice or pharmacy. Less than 1% obtained them from the internet. Studies also reveal that the source of the majority of these drugs was a single legal prescriber. Opioid Knowledge Deficit Among Healthcare Providers There are significant knowledge gaps regarding appropriate and inappropriate opioid analgesic prescribing, including a lack of understanding of current research, legislation, and proper prescribing practices. Healthcare providers often have knowledge deficits that include: Understanding of addiction. At-risk opioid addiction populations. Prescription versus non-prescription opioid addiction. The belief that addiction and dependence on opioids are synonymous. The belief that opioid addiction is a psychological problem instead of a chronic painful disease. Due to a long history of misunderstanding, poor society, insufficient education for healthcare providers, and inconsistent laws, prescribing opioids has resulted in significant societal challenges. These challenges can only be addressed through comprehensive education and training. Misuse of Controlled Substances The misuse of controlled substances resulting in morbidity and mortality is rampant. According to the 2016 National Survey on Drug Use and Health conducted by the United States Department of Health and Human Services, over 10 million people misuse prescription pain medications, and over 2 million misuse sedatives, stimulants, and tranquilizers each year. The survey also identified pain relief as the most common reason for misuse. The CDC estimates that more than 40,000 individuals die each year from an opioid overdose.  Controlled Substances Three major classes of controlled substances are frequently misused—opioids, depressants, and stimulants. Opioids: Opioids are commonly prescribed for pain control by binding to mu-opioid receptors in the central nervous system (CNS), which reduces the transmission of pain signals to the brain. In addition, opioids affect receptors in the gastrointestinal tract and respiratory system. These medications are used to treat pain, diarrhea, and cough. Common opioids: Codeine: Codeine is one of the most commonly used opioid medications. This medication is at the center of the opioid addiction problem in the United States and thus is highly regulated. Codeine is primarily prescribed for pain and cough. FDA-approved indication: Pain: Codeine is used to treat mild to moderate pain. The use of codeine is recognized in chronic pain due to ongoing cancer and palliative care. However, the use of codeine to treat other types of chronic pain remains controversial. Chronic pain, defined by the International Association for the Study of Pain, is pain persisting beyond the standard tissue healing time, which is 3 months. The most common causes of non-cancer chronic pain include back pain, fibromyalgia, osteoarthritis, and headache. Non–FDA-approved indications: Cough: Codeine is useful in treating various etiologies that produce a chronic cough. Additionally, 46% of patients with chronic cough do not have a distinct etiology despite undergoing a proper diagnostic evaluation. In such cases, codeine has been shown to reduce both the frequency and severity of coughs. However, the evidence supporting its effectiveness in treating chronic cough is limited. The dose can vary from 15 to 120 mg/d. In specific populations such as lung cancer, codeine is indicated for managing prolonged cough, typically as 30 mg every 4 to 6 hours as needed. Restless leg syndrome: Codeine is effective in treating restless leg syndrome when given at night, especially for individuals whose symptoms are not relieved by other medications. Persistent diarrhea (palliative): Codeine and loperamide are equally effective for managing persistent diarrhea. The choice between codeine and loperamide depends on the physician's evaluation of codeine's addictive potential versus loperamide's higher cost, along with the patient's susceptibility to adverse effects. Fentanyl: Transdermal patches and intravenous formulations are commonly abused and used in combination with other drugs. Fentanyl is a synthetic opioid that is 80 to 100 times stronger compared to morphine and is often added to heroin to increase its potency. This drug can cause severe respiratory depression and death, particularly when mixed with other drugs or alcohol. Fentanyl has a high potential for addiction. Hydrocodone: Hydrocodone is a Schedule II semi-synthetic opioid medication used to treat pain. Immediate-release hydrocodone is available only in combination with other agents, such as acetaminophen and ibuprofen, and is approved by the FDA for managing pain severe enough to require an opioid analgesic and for which alternative (nonopioid) treatments are inadequate. Single-entity hydrocodone is only available in extended-release formulations and is approved by the FDA to treat persistent, severe pain requiring around-the-clock, long-term opioid therapy when alternative options are insufficient. Hydrocodone is also an antitussive and is indicated for the treatment of cough in adults. Morphine sulfate: Morphine sulfate is approved by the FDA for moderate-to-severe pain, whether acute or chronic. Most commonly used in pain control, morphine provides significant relief to patients afflicted with pain. Clinical situations that significantly benefit from medicating with morphine include managing palliative or end-of-life care, active cancer treatment, and vaso-occlusive pain during sickle cell crises. Morphine is widely used off-label for almost any condition that causes pain. In the emergency department, morphine is given for musculoskeletal pain, abdominal pain, chest pain, arthritis, and even headaches when patients fail to respond to first- and second-line agents. Although morphine is rarely used for procedural sedation, clinicians sometimes combine a low dose of morphine with a low dose of benzodiazepine, such as lorazepam, for minor procedures. Oxycodone: Oxycodone is an opioid agonist prescription medication. The immediate-release formulation is approved by the FDA for managing acute or chronic moderate-to-severe pain when alternative treatments are inadequate and opioid therapy is deemed appropriate. The extended-release formulation is approved by the FDA for managing pain severe enough to require continuous (24 h/d), long-term opioid treatment, and for which there are no alternative options to treat the pain. The oxycodone to morphine dose equivalent ratio is approximately 1:1.5 for immediate-release and 1:2 for extended-release formulations. Tramadol: Tramadol is an FDA-approved medication for pain relief. This medication has specific indications for moderate-to-severe pain. Tramadol is classified as a Schedule IV drug by the FDA. Due to its potential for abuse and addiction, tramadol should be reserved for pain that is unresponsive to other treatments, including nonopioid analgesics. Tramadol is available in 2 formulations: extended-release and immediate-release. The immediate-release form is not intended for use as an as-needed medication; instead, it is for pain of less than 1 week duration. For pain lasting more than 1 week, the extended-release form is preferred, as it is indicated for pain control under 24-hour management or an extended period. Tramadol has demonstrated off-label effectiveness in the management of premature ejaculation and restless leg syndrome that is refractory to other treatments. For the off-label use of tramadol for premature ejaculation, both sporadic and daily use is effective for treating the condition. Patients generally prefer as-needed therapy for premature ejaculation due to the lack of adverse effects compared to the daily use of tramadol. Addiction, Dependence, and Tolerance Although each of these terms is similar, healthcare providers should be aware of the differences. Addiction: The constant need for a drug despite harmful consequences. Pseudoaddiction: Constant fear of being in pain and hypervigilance; typically, there is a resolution with pain resolution. Dependence: Physical adaptation to a medication where it is necessary for normal function, and withdrawal occurs with the lack of drugs. Tolerance: The lack of expected response to a medication, increasing dose to achieve the same pain relief, resulting from CNS adaptation to the medication over time. Mainstreaming Addiction Treatment Act The Mainstreaming Addiction Treatment (MAT) Act updates federal guidelines to expand the availability of evidence-based treatment to address the opioid epidemic. The MAT Act empowers all healthcare providers with a standard controlled substance license to prescribe buprenorphine for opioid use disorder, just as they prescribe other essential medications. The MAT Act aims to help destigmatize a standard of care for opioid use disorder and integrate substance use disorder treatment across all healthcare settings.  As of December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with Schedule III authority may now prescribe buprenorphine for opioid use disorder in their practice if permitted by applicable state law, and the Substance Abuse and Mental Health Services Administration encourages practitioners to do so. Prescribers who were registered as DATA-Waiver prescribers receive a new DEA registration certificate reflecting this change; no action is required on their part. There are no longer any limits on the number of patients with opioid use disorder that a practitioner may treat with buprenorphine. Separate tracking of patients treated with buprenorphine or prescriptions written is no longer required. Pharmacy staff can now fill buprenorphine prescriptions using the prescribing authority's DEA number and do not need a DATA 2000 waiver from the prescriber. However, depending on the pharmacy, the dispensing software may still require the X-Waiver information to proceed. Practitioners are still required to comply with any applicable state limits regarding the treatment of patients with opioid use disorder. For more information or assistance, contact your State Opioid Treatment Authority.

Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor system deserve attention. Preclinical, clinical, and naturalistic studies of psychedelics have shown some evidence that they may reduce opioid and other substance use. Here, we present the results of a systematic review of clinical studies investigating the therapeutic applications of psychedelics for OUD to describe the current state of the literature and guide future clinical study design in this area. Findings indicate few studies completed using serotonergic psychedelics, with most investigating ibogaine or ketamine. In addition, findings are limited by many studies of weak design focused on opioid withdrawal, and few double-blind or placebo-controlled trials with considerable methodological heterogeneity making comparisons difficult across compounds. Most studies were found to have a high risk of bias mostly related to lack of randomization, blinding, and blinding of assessment outcomes. We outline these limitations and steps towards improving the quality of future studies of psychedelics for OUD.

There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety disorders, but very few studies have examined the inverse of this, that is, the potential for psychedelics to inflict anxiety and affective symptoms. A systematic literature search was performed and 39 papers were included in the final review to qualitatively synthesize the current literature on anxiety and affective disorders related to the use of classic psychedelics. Persisting disorders were less frequent but generally occurred in individuals who presented with several risk factors (overdose, polydrug use, unstructured recreational setting, psychosocial stress, personal/familial psychiatric histories). When psychedelics were administered in clinical studies under the framework of psychedelic-assisted therapy, the incidence of enduring anxiety and affective symptoms was low. In most cases, acute transient anxiety emerged and resolved during the dosing session without the need for additional treatment interventions. The nuance of such cases is discussed, shedding light on the role of emotional catharsis in the therapeutic process. Several suggestions are proposed to enhance patient safety including strengthening the therapeutic alliance, ensuring adequate mental preparation, acclimating to high doses and providing on-going therapeutic support.

In the past few years, psilocybin, a psychedelic compound found in "magic mushrooms" (psilocybin mushrooms), has undergone decriminalization in numerous cities across the US and has been legalized in Oregon and Colorado. Proponents of psilocybin decriminalization have emphasized its therapeutic potential in treating mental health disorders. Furthermore, psilocybin mushrooms are considered the safest psychedelic option, with lower potency and a reduced risk of overdoses and emergency hospitalizations compared to other prevalent psychedelics, such as LSD (lysergic acid diethylamide) and MDMA (3,4-methylenedioxymethamphetamine). We analyzed the impact of psilocybin reforms on public interest in psilocybin, as well as their cross-commodity effects on LSD and MDMA, utilizing extensive web-based search data. We observe a significant increase in psilocybin search volume and a notable reduction in search volume associated with LSD and MDMA. Our results are consistent nationwide across states, irrespective of their stance on psilocybin reforms. The shift in public interest toward psilocybin, which is considered the safest psychedelic, away from LSD and MDMA, carries positive implications for public health.

Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States. For many people, pain can be satisfactorily managed by existing medicines and comprehensive psychosocial treatments. For others, available treatments are either ineffective or not acceptable, due to side effects and concerns about risks. Preliminary evidence suggests that some psychedelics may be effective for certain types of pain and/or improved quality of life with increased functionality and reduced disability and distress in people whose pain may never be completely relieved. Efficacy in these quality-of-life related outcomes would be consistent with the 'reset in thinking' about chronic pain management being increasingly called for as a more realistic goal for some people as compared to complete elimination of pain. This commentary summarizes the rationale for conducting more basic research and clinical trials to further explore the potential for psychedelics in chronic pain management. Additionally, if shown to be effective, to then determine whether the effects of psychedelics are primarily due to direct antinociceptive or anti-inflammatory mechanisms, or via increased tolerability, acceptance, and sense of spirituality, that appear to at least partially mediate the therapeutic effects of psychedelics observed in psychiatric disorders such as major depression. This commentary represents a collaboration of clinical and more basic scientists examining these issues and developing recommendations for research ranging from neuropharmacology to the biopsychosocial treatment factors that appear to be as important in pain management as in depression and other disorders in which psychedelic medicines are under development. This article is part of the Special Issue on "National Institutes of Health Psilocybin Research Speaker Series".

Psychedelics are experiencing a strong renaissance and will soon be incorporated into clinical practice. However, there is uncertainty about how much harm they can cause at what doses. This review aimed to collect information on the health-hazardous doses of psychedelic substances, to be aware of the risks to which patients may be subjected. We focused on ergolamines, simple tryptamines, and phenylethylamines. We reviewed articles published in major medical and scientific databases. Studies reporting toxic or lethal doses in humans and animals were included. We followed PRISMA criteria for revisions. We identified 3032 manuscripts for inclusion. Of these, 33 were ultimately useful and gave relevant information about effects associated with high psychedelics doses. Despite having different molecular structures and different mechanisms of action, psychedelics are effective at very low doses, are not addictive, and are harmful at extremely high doses. For LSD and psilocybin, no dose has been established above which the lives of users are endangered. In contrast, MDMA appears to be the most dangerous substance, although reports are biased by recreational missuses. It seems that it is not only the dose that makes the poison. In the case of psychedelics, the set and setting make the poison.

(1) Introduction: Drug-related deaths in the UK are at concerning high levels. The unknown content and purity of illicit substances can cause unpredictable adverse effects and thus a public health risk with no sign of abating. On-site drug checking is a public health strategy that has previously been implemented, predominantly in festival settings, but without Home Office licensing. (2) Aims: The aim of this study was to pilot the UK's first pharmacist-led, Home Office-licensed community drug checking service. (3) Methods: A bespoke protocol incorporating legally, professionally and ethically binding documents was implemented. This free, confidential service ran between February and March 2019, was available to anyone over 18 who were purposefully recruited, gave informed consent and agreed to relinquish their drug sample. Samples were checked on-site within an established Substance Misuse Service (SMS) using a handheld Raman spectrometer to determine likely drug content and adulterants. In parallel, participants completed a questionnaire about their substance use and the drug sample(s) being tested. A pharmacist-led multidisciplinary approach was adopted to discuss the analytical findings. Informed by the results of the analysis and the questionnaire, people who used the service received tailored harm reduction advice. (4) Results and Discussion: The pilot operated for a total of four days over four weeks. Eleven people visited and relinquished a total of thirteen samples. Half of the participants had previously overdosed and were known to the SMS. Seventy per cent were male, all were White British individuals, 30% were employed and two people disclosed visiting from another nearby town. Samples included what was thought to be heroin, synthetic cannabinoids, stimulants, benzodiazepines and LSD and none required activation of the "alerts cascade" process. Most participants drank alcohol regularly and the concomitant use of traditional illicit drugs and prescribed medication (including opioids, anxiolytics and antidepressants) with sedating profiles was common. Given some of the ethical decisions and interpretation of the results, specialist pharmacist involvement was deemed essential. (5) Conclusions: This pilot demonstrated the proof-of-concept that a pharmacist-led Home Office-licensed drug checking service can be successfully implemented in community SMSs.

4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), commonly called "N-Bomb," is a synthetic phenethylamine with psychedelic and entactogenic effects; it was available on the Internet both as a legal alternative to lysergic acid diethylamide (LSD) and as a surrogate of 3,4-methylenedioxy-methamphetamine (MDMA), but now it has been scheduled among controlled substances. 25I-NBOMe acts as full agonist on serotonergic 5-HT2A receptors. Users are often unaware of ingesting fake LSD, and several cases of intoxication and fatalities have been reported. In humans, overdoses of "N-Bomb" can cause tachycardia, hypertension, seizures, and agitation. Preclinical studies have not yet widely investigated the rewarding properties and behavioral effects of this compound in both sexes. Therefore, by in vivo microdialysis, we evaluated the effects of 25I-NBOMe on dopaminergic (DA) and serotonergic (5-HT) transmissions in the nucleus accumbens (NAc) shell and core, and the medial prefrontal cortex (mPFC) of male and female rats. Moreover, we investigated the effect of 25I-NBOMe on sensorimotor modifications as well as body temperature, nociception, and startle/prepulse inhibition (PPI). We showed that administration of 25I-NBOMe affects DA transmission in the NAc shell in both sexes, although showing different patterns; moreover, this compound causes impaired visual responses in both sexes, whereas core temperature is heavily affected in females, and the highest dose tested exerts an analgesic effect prominent in male rats. Indeed, this drug is able to impair the startle amplitude with the same extent in both sexes and inhibits the PPI in male and female rats. Our study fills the gap of knowledge on the behavioral effects of 25I-NBOMe and the risks associated with its ingestion; it focuses the attention on sex differences that might be useful to understand the trend of consumption as well as to recognize and treat intoxication and overdose symptoms.